Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 345 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2016', provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
- The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Non-Alcoholic Steatohepatitis Overview 11
Therapeutics Development 12
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview 12
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis 13
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies 14
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes 19
Non-Alcoholic Steatohepatitis - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Non-Alcoholic Steatohepatitis - Products under Development by Companies 23
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes 29
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 30
AlbireoPharma 30
Alnylam Pharmaceuticals, Inc. 31
Aquinox Pharmaceuticals Inc. 32
Arbutus Biopharma Corporation 33
Arisaph Pharmaceuticals, Inc. 34
AstraZeneca Plc 35
BiOrion Technologies B.V. 36
Bird Rock Bio, Inc. 37
Boehringer Ingelheim GmbH 38
Bristol-Myers Squibb Company 39
Can-Fite BioPharma Ltd. 40
Cardax Pharmaceuticals, Inc. 41
Cerenis Therapeutics Holding SA 42
Conatus Pharmaceuticals Inc. 43
Connexios Life Sciences Pvt. Ltd. 44
Daiichi Sankyo Company, Limited 45
Dr. Falk Pharma GmbH 46
DURECT Corporation 47
Dynavax Technologies Corporation 48
Enanta Pharmaceuticals, Inc. 49
Exicure, Inc. 50
F. Hoffmann-La Roche Ltd. 51
Galectin Therapeutics, Inc. 52
Galmed Pharmaceuticals Ltd. 53
Genfit SA 54
GenKyoTex S.A. 55
Gilead Sciences, Inc. 56
Immuron Limited 57
Intercept Pharmaceuticals, Inc. 58
Inventiva SAS 59
Ionis Pharmaceuticals, Inc. 60
Jenrin Discovery, Inc. 61
Kissei Pharmaceutical Co., Ltd. 62
Kyorin Pharmaceutical Co., Ltd. 63
Medivation, Inc. 64
Merck & Co., Inc. 65
Metabolic Solutions Development Company, LLC 66
Naia Limited 67
NGM Biopharmaceuticals, Inc. 68
Nimbus Therapeutics, LLC 69
Nippon Chemiphar Co., Ltd. 70
Nitto Denko Corporation 71
Novartis AG 72
NovaTarg Therapeutics, Inc 73
Novo Nordisk A/S 74
Pharmaxis Limited 75
Promethera Biosciences S.A. 76
ProMetic Life Sciences Inc. 77
Protalix BioTherapeutics, Inc. 78
Regulus Therapeutics Inc. 79
Shire Plc 80
Stelic Institute & Co., Inc. 81
TaiwanJ Pharmaceuticals Co., Ltd. 82
Therapix Biosciences Ltd 83
Tobira Therapeutics, Inc. 84
Vascular Biogenics Ltd. 85
Verlyx Pharma Inc. 86
Verva Pharmaceuticals Limited 87
Viking Therapeutics, Inc. 88
Virobay Inc. 89
Zafgen Inc. 90
Zydus Cadila Healthcare Limited 91
Non-Alcoholic Steatohepatitis - Therapeutics Assessment 92
Assessment by Monotherapy Products 92
Assessment by Combination Products 93
Assessment by Target 94
Assessment by Mechanism of Action 99
Assessment by Route of Administration 103
Assessment by Molecule Type 105
Drug Profiles 107
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 107
(leucine + PDE5 Inhibitor) - Drug Profile 108
A-4250 - Drug Profile 109
AM-0010 - Drug Profile 110
AQX-1125 - Drug Profile 112
Aramchol - Drug Profile 115
ARI-3037MO - Drug Profile 118
bertilimumab - Drug Profile 120
BMS-986036 - Drug Profile 122
BMS-986171 - Drug Profile 124
BOT-191 - Drug Profile 125
CDX-085 - Drug Profile 126
cenicriviroc mesylate - Drug Profile 128
CER-209 - Drug Profile 130
CF-102 - Drug Profile 131
CNX-014 - Drug Profile 133
CNX-023 - Drug Profile 134
CNX-024 - Drug Profile 135
CNX-025 - Drug Profile 136
DRX-065 - Drug Profile 137
DUR-928 - Drug Profile 138
DV-1179 - Drug Profile 140
EDP-305 - Drug Profile 142
elafibranor - Drug Profile 143
emricasan - Drug Profile 146
etanercept biosimilar - Drug Profile 148
GKT-831 - Drug Profile 149
GRMD-02 - Drug Profile 150
GS-9674 - Drug Profile 153
HepaStem - Drug Profile 155
IMM-124E - Drug Profile 157
IONIS-DGAT2Rx - Drug Profile 159
IVA-337 - Drug Profile 160
JD-5037 - Drug Profile 161
JKB-119 - Drug Profile 162
JKB-121 - Drug Profile 163
linagliptin - Drug Profile 164
liraglutide (recombinant) - Drug Profile 165
LJN-452 - Drug Profile 168
MAT-8800 - Drug Profile 169
MDV-4463 - Drug Profile 170
methazolamide - Drug Profile 171
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Metabolic and Infectious Diseases - Drug Profile 173
MSDC-0602 - Drug Profile 175
NC-101 - Drug Profile 177
NC-2400 - Drug Profile 178
ND-630 - Drug Profile 179
ND-654 - Drug Profile 180
ND-L02s0201 - Drug Profile 182
NDI-010976 - Drug Profile 184
NGM-282 - Drug Profile 185
norursodeoxycholic acid - Drug Profile 187
NP-201 - Drug Profile 189
obeticholic acid - Drug Profile 190
Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile 193
PBI-4050 - Drug Profile 194
pentamidine isethionate - Drug Profile 196
Px-103 - Drug Profile 198
PXS-4728A - Drug Profile 199
PXS-5033A - Drug Profile 200
PZ-235 - Drug Profile 201
remogliflozin etabonate - Drug Profile 202
RG-125 - Drug Profile 205
RG-6125 - Drug Profile 206
RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders - Drug Profile 208
RYI-018 - Drug Profile 209
saroglitazar - Drug Profile 210
selonsertib - Drug Profile 211
simtuzumab - Drug Profile 212
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile 214
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 215
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 216
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 217
Small Molecules to Inhibit MLK3 for Non-Alcoholic Steatohepatitis - Drug Profile 218
solithromycin - Drug Profile 219
SR-9238 - Drug Profile 222
STNM-09 - Drug Profile 223
TGFTX-3 - Drug Profile 224
tipelukast - Drug Profile 225
TKM-HTG - Drug Profile 227
TRX-318 - Drug Profile 228
VB-201 - Drug Profile 229
VBY-376 - Drug Profile 231
VK-0214 - Drug Profile 232
VK-2809 - Drug Profile 233
volixibat potassium - Drug Profile 235
VVP-100-X - Drug Profile 236
ZGN-839 - Drug Profile 237
Non-Alcoholic Steatohepatitis - Recent Pipeline Updates 238
Non-Alcoholic Steatohepatitis - Dormant Projects 327
Non-Alcoholic Steatohepatitis - Discontinued Products 329
Non-Alcoholic Steatohepatitis - Product Development Milestones 330
Featured News & Press Releases 330
Appendix 338
Methodology 338
Coverage 338
Secondary Research 338
Primary Research 338
Expert Panel Validation 338
Contact Us 338
Disclaimer 339

List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2016 18
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Development by Companies, H1 2016 (Contd..1) 21
Number of Products under Development by Companies, H1 2016 (Contd..2) 22
Number of Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Development by Companies, H1 2016 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Late Stage Development, H1 2016 26
Comparative Analysis by Clinical Stage Development, H1 2016 27
Comparative Analysis by Early Stage Development, H1 2016 28
Products under Development by Companies, H1 2016 29
Products under Development by Companies, H1 2016 (Contd..1) 30
Products under Development by Companies, H1 2016 (Contd..2) 31
Products under Development by Companies, H1 2016 (Contd..3) 32
Products under Development by Companies, H1 2016 (Contd..4) 33
Products under Development by Companies, H1 2016 (Contd..5) 34
Products under Investigation by Universities/Institutes, H1 2016 35
Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H1 2016 36
Non-Alcoholic Steatohepatitis - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 37
Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 38
Non-Alcoholic Steatohepatitis - Pipeline by Arbutus Biopharma Corporation, H1 2016 39
Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 40
Non-Alcoholic Steatohepatitis - Pipeline by AstraZeneca Plc, H1 2016 41
Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H1 2016 42
Non-Alcoholic Steatohepatitis - Pipeline by Bird Rock Bio, Inc., H1 2016 43
Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 44
Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H1 2016 45
Non-Alcoholic Steatohepatitis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 46
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 47
Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 48
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 49
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 50
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 51
Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 52
Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H1 2016 53
Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H1 2016 54
Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H1 2016 55
Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H1 2016 56
Non-Alcoholic Steatohepatitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 57
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H1 2016 58
Non-Alcoholic Steatohepatitis - Pipeline by Galmed Pharmaceuticals Ltd., H1 2016 59
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H1 2016 60
Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H1 2016 61
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H1 2016 62
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H1 2016 63
Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 64
Non-Alcoholic Steatohepatitis - Pipeline by Inventiva SAS, H1 2016 65
Non-Alcoholic Steatohepatitis - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 66
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H1 2016 67
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 68
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 69
Non-Alcoholic Steatohepatitis - Pipeline by Medivation, Inc., H1 2016 70
Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H1 2016 71
Non-Alcoholic Steatohepatitis - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016 72
Non-Alcoholic Steatohepatitis - Pipeline by Naia Limited, H1 2016 73
Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016 74
Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H1 2016 75
Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 76
Non-Alcoholic Steatohepatitis - Pipeline by Nitto Denko Corporation, H1 2016 77
Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H1 2016 78
Non-Alcoholic Steatohepatitis - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 79
Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H1 2016 80
Non-Alcoholic Steatohepatitis - Pipeline by Pharmaxis Limited, H1 2016 81
Non-Alcoholic Steatohepatitis - Pipeline by Promethera Biosciences S.A., H1 2016 82
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H1 2016 83
Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 84
Non-Alcoholic Steatohepatitis - Pipeline by Regulus Therapeutics Inc., H1 2016 85
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H1 2016 86
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., Inc., H1 2016 87
Non-Alcoholic Steatohepatitis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 88
Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H1 2016 89
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H1 2016 90
Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H1 2016 91
Non-Alcoholic Steatohepatitis - Pipeline by Verlyx Pharma Inc., H1 2016 92
Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H1 2016 93
Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H1 2016 94
Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H1 2016 95
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H1 2016 96
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 97
Assessment by Monotherapy Products, H1 2016 98
Assessment by Combination Products, H1 2016 99
Number of Products by Stage and Target, H1 2016 101
Number of Products by Stage and Mechanism of Action, H1 2016 106
Number of Products by Stage and Route of Administration, H1 2016 110
Number of Products by Stage and Molecule Type, H1 2016 112
Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H1 2016 244
Non-Alcoholic Steatohepatitis - Dormant Projects, H1 2016 333
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H1 2016 334
Non-Alcoholic Steatohepatitis - Discontinued Products, H1 2016 335